Literature DB >> 30627345

Malaria vaccines as prevention strategies: for more studies on community perception.

Camila H Coelho1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30627345      PMCID: PMC6307060          DOI: 10.4314/mmj.v30i3.1

Source DB:  PubMed          Journal:  Malawi Med J        ISSN: 1995-7262            Impact factor:   0.875


× No keyword cloud information.
Proper implementation of efficient malaria control tools is essential to program success and public health. Millions of lives are affected annually due to the disease, and despite widespread treatment and prevention efforts, malaria remains a scourge on the African continent1. Important strategies to prevent the disease involve (1) use of vector control measures, such as insecticide-treated nets (ITN) or indoor residual spray (IRS) and (2) the development of vaccines that protect humans or reduce transmission. Successful implementation of these strategies can result in significant malaria reduction2, but this requires careful consideration of the communities in which these strategies are implemented. A deep understanding of community perceptions and expectations is fundamental to crafting an effective malaria reduction strategy. In the June 2018 Malawi Medical Journal issue Parker et al. addresses important questions regarding the assessment of community perception in malaria-endemic areas3. The authors discussed the practical limitations of bed net usage based on common behaviours that perhaps were not considered during program design; for example, in the evening, many community members chat with neighbours outside prior to going to bed, and despite proper bed net usage, they can still contract malaria. This may foster the perception that ITNs are ineffective. Further, understanding community perceptions will not only identify challenges and limitations, but may also reveal possible improvements, solutions, and alternative strategies. One common perception is that insect repellents could be provided for routine use by the community, and not just by tourists. In addition, engaged community members are ultimately responsible for social mobilization, increasing public awareness, and education on prevention efforts. While several studies have evaluated community perception on vector control, a strategy successfully implemented in the field, few have analyzed the acceptability of malaria vaccines, a much newer approach for malaria control and eradication. Many types of malaria vaccines are currently under development and several are being tested in clinical trials4, but some questions related to malaria vaccines need evaluation. Among the three countries selected for pilot implementation of RTS,S vaccine, Ghana and Kenya have published studies assessing community perceptions of malaria vaccines5,6 and studies in Malawi will be similarly important. Intramuscular delivery of malaria vaccines is generally well-accepted7, but the protection achieved by this route is relatively modest and short-lived8. In contrast, intravenous delivery may confer a higher level of protection9,10 but we still do not know how communities view the implementation of an intravenous vaccine. Several questions need to be addressed in future studies of malaria vaccines: can the community understand, accept, and promote the idea of receiving a whole organism vaccine? What do people in endemic areas think about vaccines made with genetically attenuated parasites? Are they receptive to the idea of receiving a transmission-blocking vaccine that can protect the community, but not themselves directly? Listening to the community can improve the strategies already implemented or in development. Let's hear what they have to say.
  8 in total

1.  Perceptions of malaria and vaccines in Kenya.

Authors:  David Ojakaa; Emmanuel Yamo; Yvette Collymore; Antoinette Ba-Nguz; Allison Bingham
Journal:  Hum Vaccin       Date:  2011-10-01

2.  Protection against Plasmodium falciparum malaria by PfSPZ Vaccine.

Authors:  Judith E Epstein; Kristopher M Paolino; Thomas L Richie; Martha Sedegah; Alexandra Singer; Adam J Ruben; Sumana Chakravarty; April Stafford; Richard C Ruck; Abraham G Eappen; Tao Li; Peter F Billingsley; Anita Manoj; Joana C Silva; Kara Moser; Robin Nielsen; Donna Tosh; Susan Cicatelli; Harini Ganeshan; Jessica Case; Debbie Padilla; Silas Davidson; Lindsey Garver; Elizabeth Saverino; Tooba Murshedkar; Anusha Gunasekera; Patrick S Twomey; Sharina Reyes; James E Moon; Eric R James; Natasha Kc; Minglin Li; Esteban Abot; Arnel Belmonte; Kevin Hauns; Maria Belmonte; Jun Huang; Carlos Vasquez; Shon Remich; Mary Carrington; Yonas Abebe; Amy Tillman; Bradley Hickey; Jason Regules; Eileen Villasante; B Kim Lee Sim; Stephen L Hoffman
Journal:  JCI Insight       Date:  2017-01-12

3.  Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.

Authors:  Mahamadou S Sissoko; Sara A Healy; Abdoulaye Katile; Freda Omaswa; Irfan Zaidi; Erin E Gabriel; Bourama Kamate; Yacouba Samake; Merepen A Guindo; Amagana Dolo; Amadou Niangaly; Karamoko Niaré; Amatigue Zeguime; Kourane Sissoko; Hama Diallo; Ismaila Thera; Kelly Ding; Michael P Fay; Elise M O'Connell; Thomas B Nutman; Sharon Wong-Madden; Tooba Murshedkar; Adam J Ruben; Minglin Li; Yonas Abebe; Anita Manoj; Anusha Gunasekera; Sumana Chakravarty; B Kim Lee Sim; Peter F Billingsley; Eric R James; Michael Walther; Thomas L Richie; Stephen L Hoffman; Ogobara Doumbo; Patrick E Duffy
Journal:  Lancet Infect Dis       Date:  2017-02-16       Impact factor: 25.071

4.  Malaria vaccine: WHO position paper, January 2016 - Recommendations.

Authors: 
Journal:  Vaccine       Date:  2017-04-03       Impact factor: 3.641

Review 5.  The march toward malaria vaccines.

Authors:  Stephen L Hoffman; Johan Vekemans; Thomas L Richie; Patrick E Duffy
Journal:  Vaccine       Date:  2015-08-29       Impact factor: 3.641

6.  Community perceptions of a malaria vaccine in the Kintampo districts of Ghana.

Authors:  Lawrence G Febir; Kwaku P Asante; Dan-Bright S Dzorgbo; Kojo A Senah; Timothy S Letsa; Seth Owusu-Agyei
Journal:  Malar J       Date:  2013-05-07       Impact factor: 2.979

7.  Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium.

Authors:  Camila Henriques Coelho; Justin Yai Alamou Doritchamou; Irfan Zaidi; Patrick E Duffy
Journal:  NPJ Vaccines       Date:  2017-11-30       Impact factor: 7.344

8.  Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.

Authors: 
Journal:  PLoS Med       Date:  2014-07-29       Impact factor: 11.069

  8 in total
  1 in total

1.  Stakeholder perceptions on the deployment of multiple first-line therapies for uncomplicated malaria: a qualitative study in the health district of Kaya, Burkina Faso.

Authors:  Denise Hien; Jean Moise Tanga Kaboré; Mohamadou Siribié; Issiaka Soulama; Nouhoun Barry; Adama Baguiya; Alfred Bewendtaoré Tiono; André-Marie Tchouatieu; Sodiomon Bienvenu Sirima
Journal:  Malar J       Date:  2022-06-27       Impact factor: 3.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.